[1] |
Thipsawat S. Early detection of diabetic nephropathy in patient with type 2 diabetes mellitus: A review of the literature [J]. Diab Vasc Dis Res, 2021, 18(6): 14791641211058856.
|
[2] |
Haraguchi R, Kohara Y, Matsubayashi K, et al. New insights into the pathogenesis of diabetic nephropathy: proximal renal tubules are primary target of oxidative stress in diabetic kidney [J]. Acta Histochem Cytochem, 2020 ,53(2): 21-31.
|
[3] |
Khanijou V, Zafari N, Coughlan MT, et al. Review of potential biomarkers of inflammation and kidney injury in diabetic kidney disease [J]. Diabetes Metab Res Rev, 2022, 38(6): e3556.
|
[4] |
张岱, 叶山东. 钠-葡萄糖共转运蛋白2抑制剂抗氧化应激防治糖尿病肾脏疾病的研究进展 [J]. 中国糖尿病杂志, 2021, 29(8): 633-636.
|
[5] |
黄敏, 陈颖, 成水芹, 等. 骨化三醇联合坎地沙坦对早期糖尿病肾病的疗效及对血清Klotho与Vaspin水平的影响 [J]. 中国现代医学杂志, 2020, 30(7): 53-58.
|
[6] |
李美晔, 曲卫, 钱颖. 2型糖尿病患者体质指数与糖尿病肾病预后的相关性分析 [J]. 标记免疫分析与临床, 2021, 28(3): 431-434.
|
[7] |
Radellini S, Vigneri E, Guarnotta V, et al. One year of dapaglifozin add-on therapy ameliorates surrogate indexes of insulin resistance and adiposity in patients with type 2 diabetes mellitus [J]. Diabetes Ther, 2021, 12(6): 1677-1688.
|
[8] |
Huang Y, Lu W, Lu H. The clinical efficacy and safety of dapagliflozin in patients with diabetic nephropathy [J]. Diabetol Metab Syndr, 2022, 14(1): 47.
|
[9] |
林敏. 达格列净联合短期胰岛素强化治疗对初治2型糖尿病患者代谢指标的影响 [J/CD]. 中华肥胖与代谢病电子杂志, 2022, 8(1): 24-29.
|
[10] |
Müller-Wieland D, Kellerer M, Cypryk K, et al. Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes [J]. Diabetes Obes Metab, 2018, 20(11): 2598-2607.
|
[11] |
Weber MA, Mansfield TA, Cain VA, et al. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study [J]. Lancet Diabetes Endocrinol, 2016, 4(3): 211-220.
|
[12] |
Jongs N, Greene T, Chertow GM, et al. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial [J]. Lancet Diabetes Endocrinol, 2021, 9(11): 755-766.
|
[13] |
Jongs N, Chertow GM, Greene T, et al. Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD [J]. J Am Soc Nephrol, 2022, 33(11): 2094-2107.
|
[14] |
陈莉明. 聚焦肾小管损伤在糖尿病肾脏病诊治中的价值 [J]. 中华糖尿病杂志, 2021, 13(10): 921-925.
|
[15] |
连明珠, 赵莹, 康静, 等. 达格列净对早期2型糖尿病肾病患者肾小球和肾小管功能的影响 [J]. 中国现代医学杂志, 2021, 31(2): 13-18.
|
[16] |
Tang L, Wu Y, Tian M, et al. Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes [J]. Am J Physiol Endocrinol Metab, 2017, 313(5): E563-E576.
|
[17] |
Yao D, Wang S, Wang M, et al. Renoprotection of dapagliflozin in human renal proximal tubular cells via the inhibition of the high mobility group box 1receptor for advanced glycation end productsnuclear factorκB signaling pathway [J]. Mol Med Rep, 2018, 18(4): 3625-3630.
|
[18] |
Typiak M, Piwkowska A. Antiinflammatory Actions of Klotho: Implications for Therapy of Diabetic Nephropathy [J]. Int J Mol Sci, 2021, 22(2): 956
|
[19] |
Bob F, Schiller A, Timar R, et al. Rapid decline of kidney function in diabetic kidney disease is associated with high soluble Klotho levels [J]. Nefrologia (Engl Ed), 2019, 39(3): 250-257.
|
[20] |
丁华琳, 李扬扬, 于丰源, 等. 达格列净通过Klotho/TGF-β1通路抑制糖尿病肾病大鼠肾纤维化的作用 [J]. 山东大学学报(医学版), 2020, 58(03): 75-80.
|
[21] |
Zaibi N, Li P, Xu SZ. Protective effects of dapagliflozin against oxidative stress-induced cell injury in human proximal tubular cells [J]. PLoS One, 2021, 16(2): e0247234.
|